Novel combination of IDO1 inhibitor and immune checkpoint inhibitor proves active in select solid tumors.
In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.
A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.
First presentation of efficacy data suggests checkpoint inhibitor combination is effective in these patients, with intracranial ORR of 55%.
Combination treatment doubled ORR vs ipilimumab alone with no unexpected toxicity.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.